Stefan Mathias Larson
Chief Executive Officer at Mosaic Biomedicals SL
Net worth: 15 M $ as of 30/03/2024
Profile
Stefan Mathias Larson was the founder of Northern Biologics, Inc. (founded in 2014) where he held the title of Chief Executive Officer & Director from 2014 to 2017.
He is currently the Chief Executive Officer & Sole Director at Mosaic Biomedicals SL, Director at MaRS Discovery District, Director at eFFECTOR Therapeutics Operations, Inc., Director at Apnimed, Inc., Board of Director at MaRS Discovery District (Venture Capital), Director at Turnstone Biologics, Inc., Director at Prilenia Therapeutics BV, Director at Contineum Therapeutics, Inc., and Venture Partner at Sectoral Asset Management Inc (Private Equity).
Dr. Larson previously worked as a Director at Turnstone Biologics Corp.
Dr. Larson's education includes a graduate degree from the University of Toronto, an undergraduate degree from McGill University, and a doctorate degree from Stanford University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 04/04/2024 | 950,886 ( 4.06% ) | 15 M $ | 30/03/2024 |
Stefan Mathias Larson active positions
| Companies | Position | Start |
|---|---|---|
MaRS Discovery District
 MaRS Discovery District Miscellaneous Commercial ServicesCommercial Services MaRS Discovery District owns and operates a convergence center. It offers business research, information technology; pharmaceutical, optical sciences advisory and start up business assistance services. The company was founded in 2000 and is headquartered in Toronto, Canada. | Director/Board Member | 01/10/2015 |
Mosaic Biomedicals SL
 Mosaic Biomedicals SL Hospital/Nursing ManagementHealth Services Mosaic Biomedicals SL develops personalized cancer treatments. It is engaged in the realization and development of scientific and technical research projects in the field of oncological and tumor diseases. The company was founded by Joan Seoane, Judit Anido Folgueira and José Baselga on April 19, 2013 and is headquartered in Barcelona, Spain. | Chief Executive Officer | - |
eFFECTOR Therapeutics Operations, Inc.
 eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Director/Board Member | - |
Sectoral Asset Management Inc (Private Equity)
 Sectoral Asset Management Inc (Private Equity) Investment ManagersFinance Sectoral Asset Management Inc (Private Equity) (Sectoral Asset Management) is a private equity subsidiary of Sectoral Asset Management, Inc. founded in 2008 by Michael Sjöström. The firm is headquartered in Montréal, Quebec. | Private Equity Investor | 31/08/2018 |
Prilenia Therapeutics BV
 Prilenia Therapeutics BV BiotechnologyHealth Technology Prilenia Therapeutics BV develops and manufactures pharmaceuticals. The company was founded in 2018 and is headquartered in Naarden, the Netherlands. | Director/Board Member | - |
Turnstone Biologics, Inc.
 Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Director/Board Member | - |
MaRS Discovery District (Venture Capital)
 MaRS Discovery District (Venture Capital) Investment ManagersFinance MaRS Discovery District (Venture Capital) is a venture capital subsidiary of MaRS Discovery District founded in 2000 by Murray McCaig. The firm is headquartered in Toronto, Canada. | Director/Board Member | - |
Apnimed, Inc.
 Apnimed, Inc. BiotechnologyHealth Technology Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA. | Director/Board Member | 03/05/2022 |
Former positions of Stefan Mathias Larson
| Companies | Position | End |
|---|---|---|
| TURNSTONE BIOLOGICS CORP. | Director/Board Member | - |
| ░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
Training of Stefan Mathias Larson
| Stanford University | Doctorate Degree |
| McGill University | Undergraduate Degree |
| University of Toronto | Graduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| TURNSTONE BIOLOGICS CORP. | Health Technology |
| Private companies | 10 |
|---|---|
MaRS Discovery District
MaRS Discovery District Miscellaneous Commercial ServicesCommercial Services MaRS Discovery District owns and operates a convergence center. It offers business research, information technology; pharmaceutical, optical sciences advisory and start up business assistance services. The company was founded in 2000 and is headquartered in Toronto, Canada. | Commercial Services |
MaRS Discovery District (Venture Capital)
MaRS Discovery District (Venture Capital) Investment ManagersFinance MaRS Discovery District (Venture Capital) is a venture capital subsidiary of MaRS Discovery District founded in 2000 by Murray McCaig. The firm is headquartered in Toronto, Canada. | Finance |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Commercial Services |
Mosaic Biomedicals SL
Mosaic Biomedicals SL Hospital/Nursing ManagementHealth Services Mosaic Biomedicals SL develops personalized cancer treatments. It is engaged in the realization and development of scientific and technical research projects in the field of oncological and tumor diseases. The company was founded by Joan Seoane, Judit Anido Folgueira and José Baselga on April 19, 2013 and is headquartered in Barcelona, Spain. | Health Services |
Northern Biologics, Inc.
 Northern Biologics, Inc. Hospital/Nursing ManagementHealth Services Northern Biologics Inc. operates as an early-stage biologics company. It develops a portfolio of antibody-based therapeutics for oncology and fibrosis. The company was founded by Jason Moffat, Rob Rottapel, Benjamin G. Neel, Sachdev Sidhu, Brad Wouters, and Stefan Larson in June 2014 and is headquartered in Toronto, Canada. | Health Services |
Turnstone Biologics, Inc.
Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Health Technology |
Sectoral Asset Management Inc (Private Equity)
Sectoral Asset Management Inc (Private Equity) Investment ManagersFinance Sectoral Asset Management Inc (Private Equity) (Sectoral Asset Management) is a private equity subsidiary of Sectoral Asset Management, Inc. founded in 2008 by Michael Sjöström. The firm is headquartered in Montréal, Quebec. | Finance |
Apnimed, Inc.
Apnimed, Inc. BiotechnologyHealth Technology Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA. | Health Technology |
| Pipeline Therapeutics, Inc. | |
Prilenia Therapeutics BV
Prilenia Therapeutics BV BiotechnologyHealth Technology Prilenia Therapeutics BV develops and manufactures pharmaceuticals. The company was founded in 2018 and is headquartered in Naarden, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Stefan Mathias Larson
